Scientists hunt for relapse clues in childhood leukemia

NCT ID NCT06649253

Recruiting now Knowledge-focused Sponsor: Rennes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why 20% of children with B-cell acute lymphoblastic leukemia (B-ALL) relapse after treatment. Researchers will collect bone and blood samples from 50 newly diagnosed children at three key points during therapy. They will study how a protein called CD9 is regulated, which may help predict or understand relapses. This is an observational study, not a treatment trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell childhood acute lymphoblastic leukemia childhood acute lymphoblastic leukemia leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, LYMPHOBLASTIC, ACUTE, PEDIATRIC

Contacts and locations

Locations

CHU Angers
RECRUITING

Angers, France
CHU Brest
RECRUITING

Brest, France
CHU Rennes
RECRUITING

Rennes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.